Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 338

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Recombinant Human Erythropoietin for Patients with AIDS Treated with Zidovudine

Open access
Fischl, Margaret, Galpin, Jeffrey E., Levine, James D., Groopman, Jerome E., Henry, David H., Kennedy, Peter, Miles, Steven, Robbins, William, Starrett, Barbara, Zalusky, Ralph, Abels, Robert I., Tsai, Huei C., Rudnick, Seth A.·1990·New England Journal of Medicine

Abstract

Bone marrow suppression and anemia are frequent side effects of treatment of the acquired immunodeficiency syndrome (AIDS) with zidovudine (formerly azidothymidine [AZT]). We conducted a randomized, double-blind, placebo-controlled clinical trial of recombinant human erythropoietin (100 U per kilogram of body weight thrice weekly by intravenous bolus) in 63 patients with AIDS treated with zidovudine (29 in the erythropoietin group and 34 in the placebo group). Reductions in the number of units of red cells transfused and the number of patients given transfusions per month became apparent in the second and third months of the trial. The reductions were observed in patients with endogenous erythropoietin levels less than or equal to 500 IU per liter at base line, but not in patients whose levels were greater than 500 IU per liter at the beginning of the study. Although the hematocrit and hemoglobin level were not used as the primary criteria of efficacy because the patients received transfusions when their physicians decided that they needed them, a significantly higher rate of increase in the hematocrit was observed in the patients treated with recombinant human erythropoietin whose levels of endogenous erythropoietin were less than or equal to 500 IU per liter (0.00353 points per week) than in the patients given placebo (0.00116 points per week). This effect was not seen in patients with higher levels of endogenous erythropoietin. Serious side effects did not occur more often in the group treated with erythropoietin than in the placebo group. We conclude that recombinant human erythropoietin may be useful in patients with AIDS treated with zidovudine, although the indicators for its use remain to be clarified.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejm199005243222103

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 338

Metadata

Authors
Fischl, M., Galpin, J. E., Levine, J. D., Groopman, J. E., Henry, D. H., Kennedy, P., Miles, S., Robbins, W., Starrett, B., Zalusky, R., Abels, R. I., Tsai, H. C., & Rudnick, S. A.
Venue
New England Journal of Medicine
Published
1990-05-24
Volume
322
Issue
21
Pages
1488-1493
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2331565502
Cited by
338
References
7
FWCI
30.59
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recombinant Human Erythropoietin for Patients with AIDS Treated with Zidovudine. https://app.cochat.ai/papers/10.1056/nejm199005243222103
The paper
Fischl, M., Galpin, J. E., Levine, J. D., Groopman, J. E., Henry, D. H., Kennedy, P., Miles, S., Robbins, W., Starrett, B., Zalusky, R., Abels, R. I., Tsai, H. C., & Rudnick, S. A. (1990). Recombinant Human Erythropoietin for Patients with AIDS Treated with Zidovudine. New England Journal of Medicine. https://doi.org/10.1056/nejm199005243222103

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.